Chronic Hepatitis News

Transplantation with hepatitis C nucleic acid test-positive kidneys in HCV-negative recipients followed by direct-acting antiviral therapy demonstrated improved patient outcomes and significant cost-savings, according to results of a recent modelling study.

Modelling results from a recent study showed that transplantation of hepatitis C-positive livers into uninfected patients with preemptive direct-acting antiviral therapy was a cost-effective strategy and could improve health outcomes, especially in those with higher MELD scores.

Results of a modeling study showed that in dense urban settings with high prevalence of hepatitis C among people who inject drugs, HCV treatment-as-prevention strategies will have little impact over 10 years unless coverage is greatly expanded.

Direct-acting antiviral therapy has offered a highly effective cure for hepatitis C. Unfortunately, curative options are not yet available for other hepatitis viruses. Researchers continue their efforts to improve treatment and ongoing care for individuals infected with hepatitis A, hepatitis B, and hepatitis D.

Results of a recent mortality profile of New York City residents with hepatitis C and hepatitis B showed that patients with HCV were significantly more likely to have HIV coinfection, hepatocellular carcinoma, and lower survival rates compared with HBV.

Treatment with tenofovir disoproxil fumarate for chronic hepatitis B did not correlate with a higher risk for worsening of renal function among patients with significant renal impairment in a study that compared therapy outcomes with Baraclude.

Population-level hepatitis C reinfection rates after direct-acting antiviral therapy were elevated among people who inject drugs due to ongoing exposure risk, according to a recently published study.

Influences that affect liver transplantation outcomes comprise numerous hepatic and extrahepatic factors, including hepatitis C infection. Patients with HCV are at risk for progression to liver damage and cirrhosis, which can affect the rate of waitlist mortality. In recent years, the introduction of direct-acting antivirals and improved management of cirrhosis have led to better outcomes post-liver transplant.

Liver disease researchers recently published internally validated models that estimated the risk for hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C based on the presence of cirrhosis and sustained virologic response outcome.

Patients with moderate-to-severe liver disease demonstrated a lower risk for venous thromboembolism compared with those without liver disease, according to a population-based study.